AVP and non-alcoholic fatty liver: When comparing plasma copeptin levels between obese+/NAFLD+ and obese+/NAFLD− patients in relation to the presence of MS, the finding of higher copeptin in presence of NAFL—both NAFLD and NASH —was confirmed in the MS group (n = 42; NAFLD− 7.1 ± 2.7 vs NAFLD+ 10 ± 5.2 pmol/L, p = 0.024; NASH− 7.7 ± 3.7 vs NASH+ 12.2 ± 5.7 pmol/L, p = 0.007), and slightly confirmed in the significantly smaller subgroup of obese patients without MS (n = 18; NAFLD− 5.9 ± 2.4 vs NAFLD+ 8 ± 2.4 pmol/L, p = 0.06; NASH− 6.5 ± 2.6 vs NASH+ 8.5 ± 0.2 pmol/L, p = 0.01).